NCT07082920View on ClinicalTrials.gov

A Study of JNJ-78278343 in Combination With JNJ-95298177 for Treatment of Prostate Cancer

PHASE1RecruitingINTERVENTIONAL
Enrollment

110

Participants

Timeline

Start Date

July 7, 2025

Primary Completion Date

September 15, 2027

Study Completion Date

September 15, 2027

Conditions
Prostatic Neoplasms
Interventions
DRUG

JNJ-78278343

JNJ-78278343 will be administered intravenously.

DRUG

JNJ-95298177

JNJ-95298177 will be administered intravenously.

Trial Locations (2)

10032

RECRUITING

Columbia University Medical Center, New York

34232

RECRUITING

Florida Cancer Specialists, Sarasota

All Listed Sponsors
lead

Janssen Research & Development, LLC

INDUSTRY